EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort

Changgon Kim, Youngil Koh, Youngwoo Jeon, Yoon Seok Choi, Seok Jin Kim, Won Seog Kim, Sang Eun Yoon

Annals of Hematology · 01.08.2026 · 105 (11)

DOI: 10.1007/s00277-026-07212-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 01.08.2026. Verfasst von Changgon Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine, 73, Goryeodae-ro Seongbuk-gu, Seoul, 0284…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Antineoplastic Agents, Immunological. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glofitamab, a CD20×CD3 bispecific antibody, has shown durable activity in relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL), but real-world data from Korean patients and after CAR-T failure remain limited. We retrospectively analyzed 46 patients with RR-DLBCL treated with glofitamab monotherapy. Response and safety were assessed in all patients, whereas the main survival and prognostic analyses were conducted in the non-bridge-intent cohort (n = 41), excluding five bridge-intent patients. Median age was 57.5 years; patients had received a median of three prior lines, and 58.7% had failed prior CAR-T. In the overall cohort, the objective response rate was 39.1% and the complete response rate was 32.6%. In the non-bridge-intent cohort, median progression-free survival (PFS) and overall survival (OS) were 2.6 and 5.9 months, respectively, after a median follow-up of 8.2 months. Median duration of response was not reached, and 10 of 15 responders remained in response. Prior CAR-T exposure was not associated with PFS or OS. A longer pre-glofitamab interval was associated with improved PFS (adjusted hazard ratio 0.51 per category increase; p = 0.018), but not OS. Patients with an interval < 1 month had an ORR of 15.4% and median PFS of 1.0 month. Cytokine release syndrome occurred in 26.1%, all Grade 1 or 2; no immune effector cell-associated neurotoxicity syndrome or treatment-related deaths occurred. Glofitamab monotherapy demonstrated clinically meaningful activity and manageable safety in heavily pretreated RR-DLBCL. In exploratory analyses, a shorter pre-glofitamab treatment interval was associated with poorer outcomes; this hypothesis-generating observation requires prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntibodies, BispecificAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedMaleAgedRetrospective StudiesRepublic of KoreaAdultTreatment OutcomeCohort StudiesAged, 80 and overRecurrenceSurvival RateNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Bispecific antibodyCAR T-cell therapyGlofitamabReal-world evidenceRelapsed or refractory diffuse large B-cell lymphoma

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine, 73, Goryeodae-ro Seongbuk-gu, Seoul, 02841, Republic of Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
  • Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 07345, Republic of Korea.
  • Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 06591, Seoul, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul, 06351, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul, 06351, Republic of Korea. starload0326@gmail.com.

Zitieren

APA

Kim, C., Koh, Y., Jeon, Y., Choi, Y. S., Kim, S. J., Kim, W. S., & Yoon, S. E. (2026). Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07212-9

Vancouver

Kim C, Koh Y, Jeon Y, Choi YS, Kim SJ, Kim WS, et al. Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07212-9

BibTeX
@article{Kim2026,
  author = {Kim, Changgon and Koh, Youngil and Jeon, Youngwoo and Choi, Yoon Seok and Kim, Seok Jin and Kim, Won Seog and Yoon, Sang Eun},
  title = {Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07212-9}
}
Kostenlos starten →